Article
Methylenetetrahydrofolate reductase polymorphism (677 C>T) predicts long time to progression in metastatic colon cancer treated with 5-fluorouracil and folinic acid.
Archives of medical research - 1 Aug 2010
Castillo-Fernández Omar, Santibáñez Miguel, Bauza Aldo, Calderillo Germán, Castro Clementina, Herrera Roberto, Serrano Alberto, Arrieta Oscar, Herrera Luis A
Abstract excerpt
BACKGROUND AND AIMS: Fluoropyrimidine-based chemotherapy is the most common treatment for unresectable metastatic colorectal cancer (m-CRC). Therapy with 5-FU/folinic acid (FA) continues to be a standard treatment in developing countries. Pharmacogenomics allows the tailoring of cancer therapy to the patient. The polymorphism 677C>T of the methylenetetrahydrofolate reductase (MTHFR) gene seems to influence the...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.
